又一款国产创新药物达成授权交易,买家是诺华

第一财经
17 Oct 2024

国产创新药物的授权许可交易活跃度继续保持。 10月17日,总部位于四川成都的百裕制药宣布,公司在前一天与诺华就一款小分子抗肿瘤药物签订独家许可协议。 根据协议,百裕制药将收到7000万美元首付款,以及可达11亿美元的开发、注册及商业化等各类里程碑付款和相应特许使用费。诺华将获得该款小分子创新药的全球独家开发及商业化权利。 成立于2005年的百裕制药,聚焦在中枢神经系统、肿瘤、自身免疫性疾病及抗衰这...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10